Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atherosclerosis
Resverlogix Receives Excellence in Technology Award
August 31st, 2007
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that is has just learned that it has been awarded the 2007 North American Excellence in Technology of the Year Award by Frost & Sullivan. "We are honored to be recognized by Frost & Sullivan for our novel therapy for cardiovascular diseases," stated Mr. Donald McCaffrey, President & CEO of Resverlogix. "This award affirms that the enhancement of HDL/ApoA-I for the reduction of atherosclerosis is an important new class of drugs for the global medical market." "Resverlogix NexVasTM PR technology for the treatment of atherosclerosis is a best-in-class technology for therapeutic drug...
Source: Drug Week (2007-08-31)
|
